It was a summer day in 2018, and the outlook could hardly have seemed more bleak for Watson Health, IBM’s self-described “moonshot” to revolutionize medicine with artificial intelligence. The operation was reeling from layoffs and sharply critical media reports, and several of its product lines had failed to meet revenue targets.
But Lisa Rometty, a vice president of the business, painted an entirely different picture at a global meeting of hundreds of employees by video conference. She proclaimed that a business trip left her “feeling on top of the world” as she described a product the company marketed as helping to save lives, even though there was no evidence to back up that claim.
Rometty said her hopefulness was based on a scene she had witnessed inside a Chinese hospital that was using Watson to help treat cancer patients. The wife of a patient had asked doctors if they could extend her husband’s life by even one or two days, Rometty recounted. It was the only thing that mattered to her.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect